Risk factors and management of choroidal effusions.
Journal
Current opinion in ophthalmology
ISSN: 1531-7021
Titre abrégé: Curr Opin Ophthalmol
Pays: United States
ID NLM: 9011108
Informations de publication
Date de publication:
01 Mar 2023
01 Mar 2023
Historique:
pubmed:
3
2
2023
medline:
11
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
Choroidal effusions are recognized as a common early postoperative complication of glaucoma surgery, and although often benign, they may cause significant ocular morbidity. This article aims to summarize current research on the risk factors and management of choroidal effusions. Glaucoma drainage device (GDD) implantation and trabeculectomy are the most commonly performed surgeries for the management of moderate to severe glaucoma. Common postoperative complications of these procedures include hypotony and the development of choroidal effusions. Choroidal effusions have recently been associated with the oral administration of certain drugs, including select monoclonal antibody, antiseizure and bisphosphonate medications. Risk factors for effusion development include specific patient characteristics such as pseudoexfoliative glaucoma, older age and hypertension. Although choroidal effusions typically resolve with medical therapy alone, surgical intervention may be required. Various methods of surgical intervention, such as surgical drainage or GDD tube ligation, can be utilized to treat choroidal effusions when conservative management with medical treatment fails, but themselves carry alternative risks that must be considered. Minimizing the incidence and duration of hypotony following ophthalmic surgery and careful monitoring of patients starting certain oral medications are important in limiting the occurrence of choroidal effusions. Risk factors for choroidal effusions have been recently identified in the literature. A better understanding of these risk factors, as well as the outcomes of choroidal effusion management, can help to reduce the occurrence of effusions overall and minimize ocular morbidity.
Identifiants
pubmed: 36730733
doi: 10.1097/ICU.0000000000000929
pii: 00055735-202303000-00011
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
162-167Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lamping KA, Bellows AR, Hutchinson BT, Afran SI. Long-term evaluation of initial filtration surgery. Ophthalmology 1986; 93:91–101.
Bellows AR, Chylack LT Jr, Hutchinson BT. Choroidal detachment. Clinical manifestation, therapy and mechanism of formation. Ophthalmology 1981; 88:1107–1115.
Gedde SJ, Herndon LW, Brandt JD, et al. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol 2012; 153:804–814. e801.
Gedde SJ, Feuer WJ, Lim KS, et al. Postoperative complications in the primary tube versus trabeculectomy study during 5 years of follow-up. Ophthalmology 2022; In press.
Budenz DL, Barton K, Feuer WJ, et al. Treatment outcomes in the Ahmed Baerveldt Comparison Study after 1 year of follow-up. Ophthalmology 2011; 118:443–452.
Barton K, Feuer WJ, Budenz DL, et al. Three-year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology 2014; 121:1547–1557. e1541.
Christakis PG, Kalenak JW, Tsai JC, et al. The Ahmed Versus Baerveldt study: five-year treatment outcomes. Ophthalmology 2016; 123:2093–2102.
Samuelson TW, Sarkisian SR Jr, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology 2019; 126:811–821.
Samuelson TW, Chang DF, Marquis R, et al. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON Study. Ophthalmology 2019; 126:29–37.
Ahmed IIK, De Francesco T, Rhee D, et al. Long-term outcomes from the HORIZON randomized trial for a Schlemm's canal microstent in combination cataract and glaucoma surgery. Ophthalmology 2022; 129:742–751.
Voskanyan L, García-Feijoó J, Belda JI, et al. Prospective, unmasked evaluation of the iStent® inject system for open-angle glaucoma: synergy trial. Adv Ther 2014; 31:189–201.
Capper SA, Leopold IH. Mechanism of serous choroidal detachment; a review and experimental study. AMA Arch Ophthalmol 1956; 55:101–113.
Haga A, Inatani M, Shobayashi K, et al. Risk factors for choroidal detachment after trabeculectomy with mitomycin C. Clin Ophthalmol 2013; 7:1417–1421.
Iwasaki K, Kakimoto H, Arimura S, et al. Prospective cohort study of risk factors for choroidal detachment after trabeculectomy. Int Ophthalmol 2020; 40:1077–1083.
Maheshwari D, Kanduri S, Kadar MA, et al. Midterm outcome of mitomycin C augmented trabeculectomy in open angle glaucoma versus angle closure glaucoma. Indian J Ophthalmol 2019; 67:1080–1084.
Schrieber C, Liu Y. Choroidal effusions after glaucoma surgery. Curr Opin Ophthalmol 2015; 26:134–142.
Gedde SJ, Herndon LW, Brandt JD, et al. Surgical complications in the Tube Versus Trabeculectomy Study during the first year of follow-up. Am J Ophthalmol 2007; 143:23–31.
Ercalik NY, Tekcan H, Mangan MS, et al. Analysis of risk factors and ocular hypotony characteristics in choroidal detachment after penetrating glaucoma surgery. Int Ophthalmol 2022; 42:3431–3440.
Rabiolo A, Leadbetter D, Anand N. Hypotony-associated complications after deep sclerectomy: incidence, risk factors, and long-term outcomes. J Glaucoma 2021; 30:e314–e326.
Volkova N, Iureva T, Shchuko A. Impact of early and delayed Nd:YAG laser goniopuncture on results of deep sclerectomy (5-years follow up period). Eur J Ophthalmol 2021; 31:2397–2404.
Rulli E, Biagioli E, Riva I, et al. Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis. JAMA Ophthalmol 2013; 131:1573–1582.
Baker ND, Barnebey HS, Moster MR, et al. Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study. Ophthalmology 2021; 128:1710–1721.
Fea AM, Laffi GL, Martini E, et al. Effectiveness of MicroShunt in patients with primary open-angle and pseudoexfoliative glaucoma: a retrospective European multicenter study. Ophthalmol Glaucoma 2022; 5:210–218.
Quaranta L, Micheletti E, Carassa R, et al. Efficacy and safety of PreserFlo(®) MicroShunt after a failed trabeculectomy in eyes with primary open-angle glaucoma: a retrospective study. Adv Ther 2021; 38:4403–4412.
Durr GM, Schlenker MB, Samet S, Ahmed IIK. One-year outcomes of stand-alone ab externo SIBS microshunt implantation in refractory glaucoma. Br J Ophthalmol 2022; 106:71–79.
Kong YXG, Chung IY, Ang GS. Outcomes of XEN45 gel stent using posterior small incision sub-tenon ab interno insertion (Semi-open) technique. Eye (Lond) 2022; 36:1456–1460.
Mansouri K, Guidotti J, Rao HL, et al. Prospective evaluation of standalone XEN gel implant and combined phacoemulsification-XEN gel implant surgery: 1-year results. J Glaucoma 2018; 27:140–147.
Cutolo CA, Negri L, Olivari S, et al. Choroidal detachment after XEN gel stent implantation. J Ophthalmol 2021; 2021:6674505.
Chen XZ, Liang ZQ, Yang KY, et al. The outcomes of XEN gel stent implantation: a systematic review and meta-analysis. Front Med (Lausanne) 2022; 9:804847.
Karimi A, Lindfield D, Turnbull A, et al. A multicentre interventional case series of 259 ab-interno Xen gel implants for glaucoma, with and without combined cataract surgery. Eye (Lond) 2019; 33:469–477.
Stoner AM, Capitena Young CE, SooHoo JR, et al. A comparison of clinical outcomes after XEN gel stent and EX-PRESS glaucoma drainage device implantation. J Glaucoma 2021; 30:481–488.
Al Owaifeer AM, AlDarrab A, Owaidhah O. Bullous choroidal detachment requiring drainage following endoscopic cyclophotocoagulation. SAGE Open Med Case Rep 2021; 9:2050313x211046720.
Ma A, Yu SWY, Wong JKW. Micropulse laser for the treatment of glaucoma: a literature review. Surv Ophthalmol 2019; 64:486–497.
Emanuel ME, Grover DS, Fellman RL, et al. Micropulse cyclophotocoagulation: initial results in refractory glaucoma. J Glaucoma 2017; 26:726–729.
Dugan C, Zheng CX, Lin MM, et al. Outcomes of Ahmed glaucoma valve implantation with viscoelastic fill at both beginning and end of surgery. J Glaucoma 2020; 29:704–710.
Raitta C, Vesti E. The effect of sodium hyaluronate on the outcome of trabeculectomy. Ophthalmic Surg 1991; 22:145–149.
Gulkilik G, Kocabora S, Engin G, et al. Sodium hyaluronate in trabeculectomy: effect on early complications. Clin Exp Ophthalmol 2006; 34:421–424.
Board RJ, Shields MB. Combined trabeculotomy-trabeculectomy for the management of glaucoma associated wih Sturge-Weber syndrome. Ophthalmic Surg 1981; 12:813–817.
Berke SJ, Bellows AR, Shingleton BJ, et al. Chronic and recurrent choroidal detachment after glaucoma filtering surgery. Ophthalmology 1987; 94:154–162.
Shin DY, Jung KI, Park HYL, Park CK. Risk factors for choroidal detachment after Ahmed Valve implantation in glaucoma patients. Am J Ophthalmol 2020; 211:105–113.
Nobl M, Freissinger S, Kassumeh S, et al. One-year outcomes of microshunt implantation in pseudoexfoliation glaucoma. PLoS One 2021; 16:e0256670.
Ford RL, Klifto MR, Knight OJ, et al. Chronic kidney disease as a predictor of postoperative choroidal effusions after glaucoma surgery. J Glaucoma 2021; 30:981–987.
Nadeau Nguyen M, Chambers W, Dores GM, et al. Association of daratumumab use with ocular events in a case series of US adults. JAMA Oncol 2022; 8:1209–1210.
Strong A, Huvard M, Olson JL, et al. Daratumumab-induced choroidal effusion: a case report and review of the literature. Clin Lymphoma Myeloma Leuk 2020; 20:e994–e997.
Rasmussen PK, Kiilgaard JF, Salomo M. Association of choroidal effusion and infusion of daratumumab. JAMA Ophthalmol 2019; 137:853–854.
Edwards RG, Vanderhoof S, Palestine A, Seibold LK. Bilateral secondary angle closure during daratumumab infusion: a case report and review of the literature. J Glaucoma 2020; 29:e83–e86.
Hu W, Chen L, Li H, Liu J. Eye disorders associated with newer antiepileptic drugs: a real-world disproportionality analysis of FDA adverse event reporting system. Seizure 2022; 96:66–73.
Areephanthu CJ, Todd AM, Valluri S, et al. Case report of a 67-year-old man with zonisamide-induced ciliochoroidal effusion syndrome. Ophthalmol Glaucoma 2020; 3:308–310.
Baradad Jurjo MC, Sanz Moreno S, Moix Gil E, et al. Zonisamide-induced choroidal effusion: a case report. J Glaucoma 2020; 29:e100–e102.
Thng ZX, Li ZK, Gan NY. Bisphosphonate-induced bilateral anterior uveitis and choroidal effusions with secondary angle closure. Retin Cases Brief Rep 2021; 15:552–555.
Williams KJ, Scholle T, Leung EH. Management of serous and hemorrhagic choroidal detachments and complications. Int Ophthalmol Clin 2022; 62:119–130.
Chu CK, Liebmann JM, Cioffi GA, et al. Reoperations for complications within 90 days after glaucoma surgery. J Glaucoma 2020; 29:344–346.
Shalaby WS, Bechay J, Myers JS, et al. Reoperation for complications within 90 days of minimally invasive glaucoma surgery. J Cataract Refract Surg 2021; 47:886–891.
Gotzaridis SV, Portaliou DM, Mela VA, et al. Anterior chamber sulfur hexafluoride (SF6) injection for the management of postsurgery hypotony in glaucoma patients. J Glaucoma 2018; 27:476–479.
WuDunn D, Ryser D, Cantor LB. Surgical drainage of choroidal effusions following glaucoma surgery. J Glaucoma 2005; 14:103–108.
Safuri S, Bar-David L, Barak Y. Minimally invasive technique for choroidal fluid drainage. Clin Ophthalmol 2020; 14:1955–1958.
Benson SE, Mandal K, Bunce CV, Fraser SG. Is posttrabeculectomy hypotony a risk factor for subsequent failure? A case control study. BMC Ophthalmol 2005; 5:7.